Genetically engineered expression of TRM-type markers CD103 or CD39 on CAR-T cells has recently been evaluated as a strategy to overcome insufficient trafficking and infiltration of solid tumors (HCC) or hematologic cancers (human Raji lymphoma). The gene discussed is ITGAE; the disease is hematopoietic and lymphoid cell neoplasm.